Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach

Author: >   >  

Publisher: Adis International

ISSN: 1170-7690

Source: PharmacoEconomics, Vol.27, Iss.1, 2009-01, pp. : 69-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract